D. McEachern

发表

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Dajun Yang, Su Qiu, Guoping Wang, 2008, Proceedings of the National Academy of Sciences.

Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.

Liu Liu, Shaomeng Wang, Chao-yie Yang, 2012, Journal of medicinal chemistry.

SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.

Shanghai Yu, Liu Liu, Wei Sun, 2014, Cancer research.

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.

Li Ding, Joshua F. McMichael, Ron Bose, 2013, Cell reports.

Radiosensitization of Head and Neck Squamous Cell Carcinoma by a SMAC-Mimetic Compound, SM-164, Requires Activation of Caspases

Shaomeng Wang, Hua Li, T. Lawrence, 2011, Molecular Cancer Therapeutics.

SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP.

Shaomeng Wang, Yi Sun, Z. Nikolovska-Coleska, 2008, Cancer research.

Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression.

Shaomeng Wang, S. Gross, J. Stuckey, 2021, Journal of medicinal chemistry.

Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction.

Liu Liu, Shaomeng Wang, James Delproposto, 2019, Journal of medicinal chemistry.

Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction.

Liu Liu, Shaomeng Wang, J. Stuckey, 2018, Angewandte Chemie.

Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.

Shaomeng Wang, D. McEachern, B. Miao, 2021, Journal of medicinal chemistry.

Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM‐406/AT‐406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer

Tao Zhang, Shaomeng Wang, D. McEachern, 2013, Biopharmaceutics & drug disposition.

Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.

Shaomeng Wang, D. McEachern, B. Miao, 2021, Journal of medicinal chemistry.

Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.

Liu Liu, Shaomeng Wang, Chao-yie Yang, 2018, Journal of medicinal chemistry.

Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment

Shaomeng Wang, Shi-Yong Sun, S. Qiu, 2011, Molecular Cancer Therapeutics.

Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors.

J. Deschamps, Liu Liu, Shaomeng Wang, 2013, Journal of the American Chemical Society.

Discovery of MD-224 as a First-in-Class, Highly Potent and Efficacious PROTAC MDM2 Degrader Capable of Achieving Complete and Durable Tumor Regression

Liu Liu, Chao-yie Yang, D. McEachern, 2019 .

A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice.

Liu Liu, Shaomeng Wang, Dajun Yang, 2013, Journal of medicinal chemistry.

Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity.

Liu Liu, Shaomeng Wang, Chao-yie Yang, 2011, Journal of medicinal chemistry.

Sequential alteration of peanut agglutinin binding-glycoprotein expression during progression of murine mammary neoplasia.

D. McEachern, J. Rak, F. Miller, 1992, British Journal of Cancer.

A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo

Shaomeng Wang, D. McEachern, Jianfeng Lu, 2020, Neoplasia.

LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.

Shaomeng Wang, Chao-yie Yang, D. McEachern, 2012, Cancer research.

Therapeutics , Targets , and Chemical Biology LRIG 1 Modulates Cancer Cell Sensitivity to Smac Mimetics by Regulating TNF a Expression and Receptor Tyrosine Kinase Signaling

Shaomeng Wang, Chao-yie Yang, D. McEachern, 2012 .

338 BM-1252 (APG-1252): a potent dual specific Bcl-2/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity

Liu Liu, Shaomeng Wang, Chao-yie Yang, 2014 .

A potent and highly efficacious Bcl-2/Bcl-xL inhibitor.

Liu Liu, Shaomeng Wang, J. Stuckey, 2013, Journal of medicinal chemistry.

Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.

Shanghai Yu, Dajun Yang, Su Qiu, 2009, Journal of medicinal chemistry.

Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development

Liu Liu, Shaomeng Wang, Dajun Yang, 2017, Journal of medicinal chemistry.

Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer

M. Ellis, Shunqiang Li, Shaomeng Wang, 2016, Molecular Cancer Therapeutics.

Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.

Liu Liu, Chao-Yie Yang, Liu Liu, 2012, Journal of medicinal chemistry.

A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.

Liu Liu, Shaomeng Wang, D. McEachern, 2013, Journal of medicinal chemistry.

A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.

Tao Zhang, Dajun Yang, Su Qiu, 2011, Journal of medicinal chemistry.

Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.

Liu Liu, Shaomeng Wang, J. Stuckey, 2017, Journal of medicinal chemistry.

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.

Liu Liu, Shaomeng Wang, D. McEachern, 2018, Journal of medicinal chemistry.

A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo.

Liu Liu, Shaomeng Wang, J. Stuckey, 2019, Cancer cell.

Growth regulation of mouse mammary tumor cells in collagen gel cultures by diffusible factors produced by normal mammary gland epithelium and stromal fibroblasts.

D. McEachern, F. Miller, B. Miller, 1989, Cancer research.

Production of a more aggressive tumor cell variant by spontaneous fusion of two mouse tumor subpopulations.

D. McEachern, F. Miller, F R Miller, 1989, Cancer research.

BM-1197: A Novel and Specific Bcl-2/Bcl-xL Inhibitor Inducing Complete and Long-Lasting Tumor Regression In Vivo

Liu Liu, Shaomeng Wang, D. McEachern, 2014, PloS one.

Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.

Liu Liu, Shaomeng Wang, J. Stuckey, 2018, Journal of Medicinal Chemistry.

Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression.

Shaomeng Wang, J. Stuckey, D. McEachern, 2021, Journal of medicinal chemistry.

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

Shaomeng Wang, Yipin Lu, T. Carey, 2008, Molecular Cancer Therapeutics.

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression

Liu Liu, Shaomeng Wang, D. McEachern, 2017, Journal of medicinal chemistry.

Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.

M. Ellis, Shunqiang Li, Liu Liu, 2017, Cancer research.

Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression.

Liu Liu, Shaomeng Wang, Dajun Yang, 2020, Journal of medicinal chemistry.

Sensitivity of human cells to mild hyperthermia.

D. McEachern, A. Martinez, P. Corry, 1993, Cancer research.

Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity

Liu Liu, Shaomeng Wang, Yi Sun, 2021, Nature Communications.

Compliance With the National SEP-1 Quality Measure and Association With Sepsis Outcomes: A Multicenter Retrospective Cohort Study*

Barrett T. Kitch, C. Rhee, T. Jones, 2018, Critical care medicine.

Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong In Vivo Antitumor Activity.

Shaomeng Wang, J. Stuckey, D. McEachern, 2020, Journal of medicinal chemistry.

Structure-Based Discovery of SD-36 as a Potent, Selective and Efficacious PROTAC Degrader of STAT3 Protein.

Liu Liu, Shaomeng Wang, J. Stuckey, 2019, Journal of medicinal chemistry.

Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles

J. Deschamps, Liu Liu, Shaomeng Wang, 2014, Journal of medicinal chemistry.

Inhibition of lung colonization at two different steps in the metastatic sequence

D. McEachern, F. Miller, C. J. Aslakson, 1991, Clinical & Experimental Metastasis.

EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development.

Shaomeng Wang, J. Stuckey, D. McEachern, 2020, Journal of medicinal chemistry.

Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment

A. Gartel, Shaomeng Wang, L. Debussche, 2015, PloS one.

Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo

Shaomeng Wang, L. Debussche, D. McEachern, 2015, Clinical Cancer Research.

Efficiency of communication between tumour cells in collagen gel cultures

D. McEachern, F. Miller, B. Miller, 1990, British Journal of Cancer.

Modulation of host resistance to metastasis in the lungs of aged retired breeder mice.

D. McEachern, F. Miller, C. J. Aslakson, 1991, Invasion and Metastasis.

Precise Conformational Control Yielding Highly Potent and Exceptionally Selective BRD4 Degraders with Strong Antitumor Activity.

Shaomeng Wang, J. Stuckey, D. McEachern, 2023, Journal of medicinal chemistry.

Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia.

Shaomeng Wang, J. Stuckey, D. McEachern, 2023, Journal of medicinal chemistry.

A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo

Wei Jiang, J. Stuckey, D. McEachern, 2023, Nature Chemical Biology.

SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression.

Shaomeng Wang, J. Stuckey, D. McEachern, 2021, ACS medicinal chemistry letters.

544 Preclinical studies of a dual Bcl-2/Bcl-xL inhibitor APG-1252 with strong anti-tumor efficacy and significantly reduced platelet toxicity

Shaomeng Wang, Dajun Yang, D. McEachern, 2014 .

Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.

D. McEachern, B. Miao, Mi Wang, 2023, Journal of medicinal chemistry.

Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.

Liu Liu, Shaomeng Wang, J. Stuckey, 2012, Journal of medicinal chemistry.

Comparison of tumor growth between HSP25‐ and HSP27‐transfected murine L929 cells in nude mice

D. McEachern, R. Blackburn, E. Armour, 1997, International journal of cancer.

Radiosensitization of Head and Neck Squamous Cell Carcinoma by a SMAC-Mimetic Compound, SM-164, Requires Activation of Caspases

Shaomeng Wang, Hua Li, T. Lawrence, 2011, Molecular Cancer Therapeutics.

Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.

Liu Liu, Shaomeng Wang, J. Stuckey, 2017, Journal of medicinal chemistry.

Reactivation of p 53 by MDM 2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer

M. Ellis, Shunqiang Li, Shaomeng Wang, 2016 .

Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9.

D. McEachern, Mi Wang, Shaomeng Wang, 2024, Journal of medicinal chemistry.

Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer.

D. McEachern, Biao Hu, Shaomeng Wang, 2024, Journal of medicinal chemistry.